Trial Profile
Clinical Trials to Compare the Pharmacokinetic Profiles of Sarpogrelate hydrochloride 300mg Sustained Release Tablet and ANPLAG Immediate Release Tablet After Multiple Oral Administration to Healthy Male Subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Sarpogrelate (Primary)
- Indications Arterial occlusive disorders; Embolism and thrombosis
- Focus Pharmacokinetics
- Sponsors KunWha Pharmaceutical
- 12 Sep 2011 New trial record